Peptide receptor radionuclide therapy with 177Lu-DOTATATE for metastatic neuroendocrine tumor occurring in association with multiple endocrine neoplasia type 1 and cushing's syndrome
Neuroendocrine tumor (NET) occurring in association with other endocrine syndromes forms a distinct entity. The aim was to assess the therapy response profile of the routine peptide receptor radionuclide therapy (PRRT) in this relatively uncommon but clinically challenging subgroup of patients. A re...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2017-04-01
|
| Serie: | World Journal of Nuclear Medicine |
| Soggetti: | |
| Accesso online: | http://www.thieme-connect.de/DOI/DOI?10.4103/1450-1147.203068 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|